Pinealon Canada: Research Peptide Overview

Pinealon is a synthetic tripeptide — just three amino acids, Glu-Asp-Arg — studied in laboratory settings as one of the short peptide bioregulators developed by Russian researchers from the 1980s onward. It is among the smallest compounds in the research peptide catalogue, and that size is central to why it is studied the way it is.

Written by the NexPept Research Team · Last updated: October 2026

This guide covers what the compound is, where the peptide bioregulator class comes from, what the published research base does and does not contain, and how NexPept documents each batch. It is an educational overview for laboratory research purposes and is not a dosing guide.

What Is Pinealon?

Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid and arginine, in that order. Written in single-letter notation those three residues are E, D and R, which is why the compound is frequently sold and indexed as the EDR peptide — the two names refer to the same molecule.

At 418.41 g/mol it is a very small molecule by peptide standards. For comparison, the metabolic research peptides in the same catalogue run past 4,000 g/mol. A tripeptide has two peptide bonds, no secondary structure to speak of, no disulfide bridges and no lipid modifications, which makes it straightforward to synthesize and unusually stable as a lyophilized powder.

That simplicity cuts both ways, and it shapes what you should actually check when sourcing it — covered in the batch section below. If you are new to this category of material, our guide explaining what research peptides are is a useful starting point.

Pinealon Properties

These are the published identifiers for the compound. Purity and batch values specific to the material NexPept ships are further down.

Where Pinealon Comes From: The Short Peptide Bioregulators

Pinealon does not come out of the same research tradition as most of the compounds it sits beside in a catalogue. It belongs to a family of very short synthetic peptides — typically two to four residues — developed primarily by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, beginning with work on tissue-derived peptide extracts in the 1980s and moving to defined synthetic sequences afterwards.

The working hypothesis behind that programme is that very short peptide sequences can interact with DNA and chromatin directly and influence gene expression in a tissue-selective way. That hypothesis is what the laboratory work in this family is designed to test, and it is the reason these compounds are studied as a group rather than individually.

Two things are worth stating plainly about this literature, because most pages selling these compounds do not.

It is small, and it is concentrated. A large share of the published work on Pinealon comes from the same research group, much of it published in Russian-language journals and in a relatively narrow set of venues. That is not an accusation of bad faith — it is a normal pattern for a research programme built around one institute — but independent replication outside that group is thin, and that is directly relevant to how much weight any single finding should carry.

It is preclinical. The Pinealon work that exists is largely cell-culture and rodent work. Published studies include reports on protection of rat offspring from prenatal hyperhomocysteinaemia with effects on later cognitive performance, and on retention of learned behaviour in rats with experimentally induced diabetes. Those are animal findings in specific experimental models. They do not describe effects in humans, and nothing in this literature supports extrapolating to human use.

Research Focus Areas

In controlled laboratory environments, Pinealon appears in work on:

• Short-peptide interaction with DNA and chromatin
• Gene expression modulation in cell-culture models
• Neuroprotection models in rodents, including oxidative-stress challenge
• Cognitive and behavioural retention studies in animal models
• Comparative work across the short peptide bioregulator family
• Peptide stability and handling research, where its small size makes it a useful reference

All of this is preclinical and confined to experimental contexts. Interpretation should be limited strictly to the laboratory data in question.

How Pinealon Compares With Other Short Research Peptides

Pinealon is routinely grouped with other short peptides from Russian research programmes, but they do not all come from the same lineage and they are not variants of each other. The sequences are genuinely different compounds.

Pinealon and Epitalon are the two in that list that share a research programme. Semax and Selank are Russian in origin as well but descend from entirely different parent molecules — a fragment of ACTH and the immunopeptide tuftsin respectively — and are studied against different questions. All four are grouped under neuro research in our catalogue.

Purity, Batch Data and Documentation

With a tripeptide, the risk profile is different from a large modified peptide, and it is worth being specific about that rather than repeating a generic purity pitch.

A three-residue sequence is easy to synthesize, so high HPLC purity figures are common and not especially hard to achieve. The failure mode that actually matters here is identity: a short sequence is also easy to get wrong, cheap to substitute, and — because so little material is involved — easy to misrepresent. Two different tripeptides can look similar on a purity line and be entirely different compounds. This is why mass spectrometry identity confirmation matters more for a compound like this than the purity percentage does, and why a certificate that reports purity without confirming identity tells you less than it appears to.

"COA available on request" is the most over-claimed phrase in this market. A certificate worth relying on names the testing laboratory, carries a lot number matching the vial in your hand, states the analytical method, and shows the chromatogram rather than a number someone typed. We publish ours instead of supplying them on request, so the material can be checked before an order is placed.

Identity and purity are confirmed by HPLC and mass spectrometry before a lot is listed, and the certificate stays published in our COA library after the batch sells out — so a result recorded against an old lot can still be traced back to its report. All new batches additionally carry endotoxin testing, which matters for cell-based work where endotoxin can confound a result independently of chemical purity, and the most-ordered products also carry heavy-metal testing.

Storage and Handling

Short lyophilized peptides are among the more stable materials in a research catalogue, but handling after delivery still affects integrity more than most buyers expect. General laboratory considerations include:

• Storage cool and dry, avoiding repeated temperature cycling
• Protection from moisture and prolonged light exposure — the arginine residue makes the powder hygroscopic enough that an improperly sealed vial will take up water
• Recording the lot number against your own inventory, so any later question about a result traces back to a specific batch and its report
• Handling under institution-approved protocols

Lyophilized powder is considerably more stable than peptide in solution, and researchers should defer to their own institution's validated protocols rather than a general guideline. More detail is in our guide to storing research peptides. NexPept does not supply preparation, reconstitution or handling instructions; those are determined by qualified personnel under your own protocols.

Sourcing Pinealon in Canada

Four things are worth checking before ordering anywhere. They apply to any supplier rather than to this compound specifically.

Documentation

Batch-specific reports, published rather than promised, with a lot number that matches your vial. For a short peptide, check specifically that the certificate confirms identity by mass spectrometry and not purity alone. One generic certificate covering a whole catalogue tells you nothing about what arrived.

Fulfilment

A stated Canadian location and courier. Material crossing the border is subject to customs holds nobody can give you a date for, and spends longer in uncontrolled conditions. Our orders ship from Ontario by tracked Canada Post — details on the shipping page.

Positioning

Research-use framing throughout. This matters more than usual for the bioregulator family, which attracts a great deal of anti-aging marketing language that the underlying literature does not support. A supplier making longevity claims about a tripeptide is telling you how the rest of the operation is run.

Pricing

Analytical testing costs money per lot, and on a low-priced short peptide it is a larger share of the unit cost than it is on an expensive one — which makes it the easiest corner to cut while still describing material as tested. For a wider walkthrough of evaluating a domestic supplier, see our Peptides Canada guide and our guide to buying research peptides in Canada.

Common Questions About Pinealon

Key Takeaways

• Pinealon is the tripeptide Glu-Asp-Arg, CAS 175175-23-2, also sold as the EDR peptide
• It belongs to the Khavinson short peptide bioregulator family, alongside Epitalon — a shared lineage, not a shared sequence
• The research base is small, largely preclinical, and concentrated in one research programme
• For a tripeptide, mass spectrometry identity confirmation matters more than the purity figure
• The current NexPept lot, NP-PINE-02, tested at 99.92% by HPLC on August 17, 2026, certificate published up front
• It is not authorized by Health Canada and is supplied for laboratory research use only

Peer-reviewed literature on this compound is indexed on PubMed, and the full NexPept catalogue of lab-tested compounds is available here.